Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Roberts, Andrew W., Davids, Matthew S., Pagel, John M., Kahl, Brad S., Puvvada, Soham D., Gerecitano, John F., Kipps, Thomas J., Anderson, Mary Ann, Brown, Jennifer R., Gressick, Lori, Wong, Shekman, Dunbar, Martin, Zhu, Ming, Desai, Monali B., Cerri, Elisa, Enschede, Sari Heitner, Humerickhouse, Rod A., Wierda, William G., Seymour, John F.
フォーマット: Artigo
言語:Inglês
出版事項: 2015
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7107002/
https://ncbi.nlm.nih.gov/pubmed/26639348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513257
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料